Barclays revised its view of several smaller mid-cap biotech stocks after the first-quarter earnings season, issuing re-ratings Monday for Prothena Corporation PLC (NASDAQ: PRTA) and Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN).
Barclays analyst Geoff Meacham downgraded Prothena from Equal Weight to Underweight and cut the price target from $14 to $12.
The analyst upgraded Achillion from Underweight to Equal Weight and maintained a $5 price target
Meacham sees limited near-term value-creating opportunities for Prothena. His reassessment of the company follows the discontinuation of its core development program in AL amyloidosis.
Other programs — namely partnerships with Roche in Parkinson's disease and Celgene Corporation (NASDAQ: CELG) in ATTR Amyloidosis — do present some upside in the longer term, the analyst said. Both are too early in their development for the analyst to ascribe significant value, he said.
Achillion has become better positioned to succeed, according to Meacham; he cited the company’s progress on shifting its focus from Hepatitis C to orphan diseases.
Given the company’s current price, the Factor-D program has not been fully priced in, warranting a higher valuation, Meacham said. Investors will likely wait to see more derisking data that's expected to be presented later this year, he said.
“We do not have enough conviction to move to Overweight, but see minimal downside risk at current levels."
Elsewhere in the sector, Barclays reviewed its investment theses on Acceleron Pharma Inc (NASDAQ: XLRN) and BioXcel Therapeutics Inc (NASDAQ: BTAI). Meacham reiterated Overweight ratings on both and maintained $54 and $15 price targets, respectively.
Shares of Prothena opened sharply lower Monday but filled most of the gap quickly. Shares were trading down 3.47 percent at $14.75 at the time of publication.
Achillion shares showed an opposite pattern, spiking 6 percent after the open before pulling back. Shares were trading down 1.76 percent at $3.64 at the time of publication.
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
Latest Ratings for PRTA
View More Analyst Ratings for PRTA
View the Latest Analyst Ratings
See more from Benzinga
- Energy Sector Growth Will Help Fuel Dillard's, BofA Says In Double Upgrade
- Morgan Stanley Is Out Positive On Apollo: 3 Reasons To Buy
- Campbell Soup's CEO Retires, Q3 Sales Fall Short Of Estimates
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.